Clinical Trial: A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer

U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT06970119) titled 'A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer' on April 27.

Brief Summary: A Phase I/IIa clinical trial to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of INR102 injection in patients with prostate cancer.

Study Start Date: May 09

Study Type: INTERVENTIONAL

Condition: Prostate Cancer

Intervention: DRUG: INR102 injection

INR102 injection is a lutetium-177 ([177Lu])-labeled radiopharmaceutical agent targeting prostate-specific membrane antigen (PSMA). It is clinically indicated for the treatm...